Oncology

Iberdomide enhances chimeric antigen receptor (CAR) T-cell therapy effectiveness in multiple myeloma, boosting immune response and cell functionality.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Teclistamab and other bispecific antibodies enhance multiple myeloma treatment but significantly increase infection risks, necessitating proactive management strategies.

Teclistamab shows promising results in newly diagnosed multiple myeloma, enhancing tolerability and achieving high rates of minimal residual disease negativity.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

Additionally, the FDA granted a provisional interchangeability designation to both biosimilars.

NCCN updated its small-cell lung cancer guidelines, introducing lurbinectedin for maintenance therapy and removing the chemotherapy-free interval for better treatment strategies.

Cemiplimab was also superior in improving progression-free survival, objective response rate, and duration of response in patients with non–small cell lung cancer (NSCLC).

The 2025 International Myeloma Society Annual Meeting unveils crucial updates to IMWG guidelines, enhancing response assessment and treatment strategies for multiple myeloma.

Promising phase 2 results for taletrectinib in ROS1+ lung cancer show significant tumor shrinkage and manageable adverse effects.

A recent phase 3 study reveals osimertinib combined with chemotherapy offers unprecedented survival rates for patients with advanced EGFR-mutated lung cancer.

Cutting-edge insights and expert discussions on multiple myeloma will be presented at the 2025 IMS Annual Meeting in Toronto, shaping future treatment standards.

World Lymphoma Day highlights the rising prevalence of lymphoma and innovative treatments, emphasizing the role of pharmacists in patient care.

When combined with an anti–PD-L1 therapy, tarlatamab significantly improves overall survival in patients with extensive-stage small cell lung cancer (ES-SCLC).

New FDA regulations are intended to enhance transparency in prescription drug advertising, empowering pharmacists to educate patients on medication risks and benefits.

A panel of 4 experts discussed the most favored nation (MFN) initiative and its impacts on research and development, market and payer distributions, and pharmacists and patients.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

The FDA approves a groundbreaking gemcitabine system, offering new hope for patients with BCG-unresponsive bladder cancer.

The treatment was generally well-tolerated in patients with ROS1-positive (ROS1+) non–small cell lung cancer (NSCLC).

Legislative efforts aim to improve oncology medication access, addressing transportation barriers and advocating for mail delivery from cancer clinics.

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

Experts discuss radon—the second leading cause of lung cancer.

Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early adverse effect management for patients starting zongertinib (Hernexeos).

Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).

Joshua K. Sabari, MD, discusses how zongertinib’s inclusion in the National Comprehensive Care Network (NCCN) guidelines represents a game-changing second-line treatment for HER2-mutant non-small cell lung cancer (NSCLC).

New research uncovers how smoking accelerates pancreatic cancer progression through immune mechanisms, revealing potential for targeted therapies and improved screening.

The FDA designates olomorasib as a breakthrough therapy, enhancing treatment options for advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutations.